In mouse models, across various cancer histologies, inhibition of the pathway using MAPK/ERK (extracellular signal–regulated kinase) inhibitors (MEKi) resulted in enhanced TILs, IFNγ production, and MHC-I expression, suggesting that combination therapy of MEKi with PD-(L)1 or CTLA-4 blockade may improve response in patients with genomic alterations in the MAPK pathway [52–54]. Here, CD274 is linked to cancer.